A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2018
At a glance
- Drugs TAK 653 (Primary)
- Indications Depressive disorders
- Focus Adverse reactions
- Sponsors Takeda
- 15 Jan 2018 Status changed from recruiting to completed.
- 12 May 2017 Treatment arms has been changed from 2 to 13.
- 12 May 2017 Planned number of patients changed from 72 to 112.